Affordable Access

deepdyve-link
Publisher Website

Cytoprotection "gone astray": Nrf2 and its role in cancer.

Authors
  • Geismann, Claudia
  • Arlt, Alexander
  • Sebens, Susanne
  • Schäfer, Heiner
Type
Published Article
Journal
OncoTargets and Therapy
Publisher
Dove Medical Press
Publication Date
Jan 01, 2014
Volume
7
Pages
1497–1518
Identifiers
DOI: 10.2147/OTT.S36624
PMID: 25210464
Source
Medline
Keywords
License
Unknown

Abstract

Nrf2 has gained great attention with respect to its pivotal role in cell and tissue protection. Primarily defending cells against metabolic, xenobiotic and oxidative stress, Nrf2 is essential for maintaining tissue integrity. Owing to these functions, Nrf2 is regarded as a promising drug target in the chemoprevention of diseases, including cancer. However, much evidence has accumulated that the beneficial role of Nrf2 in cancer prevention essentially depends on the tight control of its activity. In fact, the deregulation of Nrf2 is a critical determinant in oncogenesis and found in many types of cancer. Therefore, amplified Nrf2 activity has profound effects on the phenotype of tumor cells, including radio/chemoresistance, apoptosis protection, invasiveness, antisenescence, autophagy deficiency, and angiogenicity. The deregulation of Nrf2 can result from various epigenetic and genetic alterations directly affecting Nrf2 control or from the complex interplay of Nrf2 with numerous oncogenic signaling pathways. Additionally, alterations of the cellular environment, eg, during inflammation, contribute to Nrf2 deregulation and its persistent activation. Therefore, the status of Nrf2 as anti- or protumorigenic is defined by many different modalities. A better understanding of these modalities is essential for the safe use of Nrf2 as an activation target for chemoprevention on the one hand and as an inhibition target in cancer therapy on the other. The present review mainly addresses the conditions that promote the oncogenic function of Nrf2 and the resulting consequences providing the rationale for using Nrf2 as a target structure in cancer therapy.

Report this publication

Statistics

Seen <100 times